Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma.
Julien CALDERARO,
F Petitprez,
E Becht,
A Laurent,
TZ Hirsch,
Benoit ROUSSEAU,
Alain LUCIANI,
Giuliana AMADDEO,
J Derman,
C Charpy,
J Zucman-Rossi,
WH Fridman,
C Sautes-Fridman,
J Hepatol. 11/09/2018;pii: S0168-8278(18) : 32373-0 10.1016/j.jhep.2018.09.003
Optimal oncologic management and mTOR inhibitor introduction are safe and improve survival in kidney and liver allograft recipients with de novo carcinoma.
Benoit ROUSSEAU,
A Guillemin,
C Duvoux,
C Neuzillet,
C Tlemsani,
P Compagnon,
D Azoulay,
C Salloum,
A Laurent,
A de la Taille,
L Salomon,
I Cholley,
C Haioun,
J Dupuis,
P Wolkenstein,
MB Matignon,
P Grimbert,
C Tournigand,
Int J Cancer 28/08/2018;- : - 10.1002/ijc.31769
Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma
A Vienot,
G Beinse,
A Louvet,
L de Mestier,
A Meurisse,
F Fein,
B Heyd,
D Cleau,
C d'Engremont,
AC Dupont-Gossart,
Z Lakkis,
C Tournigand,
O Bouché,
Benoit ROUSSEAU,
C Neuzillet,
F Bonnetain,
C Borg,
D Vernerey,
J Natl Cancer Inst. 01/10/2017;109(10) : . 10.1093/jnci/djx037.
Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers part 2: Neuroendocrine tumours, hepatocellular carcinoma, and gastro-intestinal stromal tumours
C Neuzillet,
L de Mestier,
Benoit ROUSSEAU,
O Mir,
M Hebbar,
HM Kocher,
P Ruszniewski,
C Tournigand,
Pharmacol Ther. 16/07/2017;pii: S0163-7258(17) : 30166-3 10.1016/j.pharmthera.2017.07.006